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Hypoxic gene expression in chronic 
hepatitis B virus infected patients 
is not observed in state‑of‑the‑art 
in vitro and mouse infection models
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Hepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma (HCC) worldwide. The prolyl 
hydroxylase domain (PHD)‑hypoxia inducible factor (HIF) pathway is a key mammalian oxygen sensing 
pathway and is frequently perturbed by pathological states including infection and inflammation. We 
discovered a significant upregulation of hypoxia regulated gene transcripts in patients with chronic 
hepatitis B (CHB) in the absence of liver cirrhosis. We used state‑of‑the‑art in vitro and in vivo HBV 
infection models to evaluate a role for HBV infection and the viral regulatory protein HBx to drive 
HIF‑signalling. HBx had no significant impact on HIF expression or associated transcriptional activity 
under normoxic or hypoxic conditions. Furthermore, we found no evidence of hypoxia gene expression 
in HBV de novo infection, HBV infected human liver chimeric mice or transgenic mice with integrated 
HBV genome. Collectively, our data show clear evidence of hypoxia gene induction in CHB that is not 
recapitulated in existing models for acute HBV infection, suggesting a role for inflammatory mediators 
in promoting hypoxia gene expression.
HBV is a global health problem with more than 250 million people chronically infected and at least 780,000 
deaths/year from HBV-related liver diseases such as liver cirrhosis and hepatocellular carcinoma (HCC)1,2. HBV 
replicates in hepatocytes within the liver and current anti-viral treatments suppress viral replication but are not 
curative, largely due to the persistence of the viral covalently closed circular DNA (cccDNA)  reservoir3. Chronic 
hepatitis B (CHB) is a virus-associated, inflammatory liver disease and one of the leading causes of  HCC4, one 
of the fastest rising and fourth most common cause of cancer related-death world-wide5. Curative therapies 
(tumour ablation, resection or liver transplantation) are dependent on early detection, however, the majority 
of HBV and non-viral associated HCC cases are diagnosed at a late stage often resulting in a poor  prognosis6. 
Despite significant advances in our understanding of the HBV replicative life cycle, the mechanisms underlying 
HCC pathogenesis are not well  defined7.
Although liver cirrhosis is a major risk factor for developing HCC, 10–20% of HBV infected patients that 
develop HCC are non-cirrhotic, highlighting a role for HBV to promote carcinogenesis via direct and indirect 
inflammatory  mechanisms7. Three major and non-exclusive viral-dependent pathways have been proposed: (i) 
integration of viral DNA into the host genome; (ii) expression of viral oncogenic proteins and (iii) viral-driven 
changes in host gene transcription (reviewed  in8). The viral encoded regulatory hepatitis B X protein (HBx) has 
been reported to promote the expression of both viral and selected host genes, where a recent study reported 
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HBx binding to > 5,000 host genes with diverse roles in metabolism, chromatin maintenance and  carcinogenesis9. 
There is clearly an urgent need to increase our understanding of HBV mediated carcinogenesis to support the 
development of tools to identify CHB patients at risk of HCC development.
The liver receives oxygenated blood from the hepatic artery and oxygen-depleted blood via the hepatic portal 
vein, resulting in an oxygen gradient of 4–8% across the pericentral and periportal areas,  respectively10. This 
oxygen gradient has been reported to associate with liver zonation, a phenomenon where hepatocytes show 
distinct functional and structural heterogeneity across the  parenchyma11,12. Recent single-cell RNA sequencing 
analysis of the mouse liver highlights a major role for hypoxic and Wnt signalling pathways to shape liver zona-
tion profiles in the normal healthy liver with an enrichment of hypoxic gene expression in the pericentral  area13. 
Importantly, this oxygen gradient is readily perturbed in pathological states such as infection, inflammation and 
 cirrhosis14. One of the best studied oxygen sensing mechanisms is the hypoxia inducible factor (HIF)  pathway15. 
As HIF-signalling pathways are altered in many diseases, including cancer and inflammatory conditions, phar-
macological approaches to modulate HIF activity offer promising therapeutic  opportunities16,17. When oxygen 
is abundant, newly synthesised HIFα subunits, including HIF-1α and HIF-2α isomers, are rapidly hydroxylated 
by prolyl-hydroxylase domain (PHD) proteins and targeted for poly-ubiquitination and proteasomal degrada-
tion. In contrast when oxygen is limited these HIFα subunits translocate to the nucleus, dimerize with HIF-β 
and positively regulate the transcription of a myriad of host genes involved in cell metabolism, proliferation, 
angiogenesis and immune regulation. Dai et al. reported that increased HIF-1α mRNA and protein expression in 
HCC are prognostic for more advanced disease stages and poor overall survival post-surgical tumour  resection18. 
Furthermore, Xiang et al. and Zheng et al. showed that HIF-1α protein expression is predictive of HCC lymph 
node metastasis and vascular  invasion19,20. Thus, HIF signalling could have an important role in progressive liver 
disease and HCC  development14.
In addition to hypoxia, inflammation, oxidative stress and viral infection can promote HIF-transcriptional 
activity. The host inflammatory mediators nuclear factor-κB (NF-κB) and tumor necrosis factor-α (TNF-α) 
induce HIF-1α  transcription21,22. Reactive oxygen species (ROS) produced by inflammatory cells provide a fur-
ther mechanism for inflammation-driven HIF-signalling23–25. Several viruses induce the HIF signaling pathway 
including hepatitis C  virus26–28, human  papillomavirus29, Kaposi sarcoma-associated  herpesvirus30 and human 
 cytomegalovirus31. Several reports have suggested that HBx can interact with and stabilize  HIFs32–40, however, 
this proposed HBx-HIF interplay awaits validation in HBV replication in vitro and in vivo model systems.
In this study, we report a significant upregulation of hypoxic gene expression in a cohort of chronic HBV 
infected  patients41. Our studies to investigate the underlying mechanism using state-of-the-art in vitro and 
in vivo HBV transgenic mice and human liver chimeric mice models show limited evidence of hypoxic gene 
expression. These studies highlight a major role of liver inflammation and a complex interplay between HBV 
and HIF signalling in the chronic infected liver that is not recapitulated by current infection-competent model 
systems. Collectively, our data show clear evidence of hypoxia-driven gene expression in CHB in the absence of 
cirrhosis or HCC development that may play a role in driving hepatocarcinogenesis.
Results
Increased hypoxia gene signature in chronic hepatitis B. To determine whether there is any associa-
tion between hypoxic responsive transcription and CHB, we performed Gene Set Enrichment Analysis (GSEA) 
on microarray data from a cohort of chronic HBV infected patients (n = 90) that were free of cirrhosis or HCC 
and uninfected control subjects (healthy, n = 6)41. We used a panel of 43 hypoxia gene signatures obtained from 
the Molecular Signatures Database (MSigDB v 7.0)42, that included hypoxia upregulated genes from diverse 
tissues and cancer types. We observed a significant enrichment (FDR < 0.05) of 19 gene sets in the CHB cohort 
(Fig.  1a). Since hypoxic-transcriptional responses can vary between cell and tissue  types43 and none of the 
MSigDB signatures were liver-derived (Supplementary Table 1), we analysed an RNA-sequencing (RNA-seq) 
transcriptome of human hepatoma derived HepG2  cells44 (0.5% oxygen for 16  h). We identified 80 hypoxic 
upregulated genes (greater than twofold change, FDR < 0.05) (Supplementary Table 2) and GSEA showed an 
enrichment (FDR = 0.077) in the CHB cohort (Fig. 1b). To further validate these results, we analysed the acute 
transcriptional response of primary human hepatocytes (PHHs)45 cultured under 1% oxygen for 4 h and iden-
tified 113 upregulated genes (FC > 2; FDR < 0.05) and GSEA showed an enrichment in CHB (Supplementary 
Fig. 2a). Since PHHs can rapidly de-differentiate and lose hepatocyte-specific function in vitro46,47, it was reas-
suring to observe an overlap of hypoxic regulated genes in HepG2 and PHHs (Supplementary Fig. 2b). 
CHB reflects a dynamic interaction between virus infected hepatocytes and immune cells and periods of 
active hepatitis, as measured by the elevated activity of the liver enzyme alanine aminotransferase (ALT), asso-
ciate with increased  viremia48. Grouping our CHB cohort by ALT activity showed a significant enrichment 
(FDR = 0.110) of the hypoxic HepG2 derived gene set in patients with elevated ALT (ALT > 40 IU/mL) (n = 57) 
compared to those with normal ALT (n = 25) (Fig. 1c). To evaluate whether hypoxic gene expression is observed 
in other inflammatory liver disease we studied a cohort of hepatitis C virus (HCV) infected patients with cir-
rhosis (n = 41)49 and observed a significant enrichment of the hypoxic HepG2 gene signature (FDR = 0.006) in 
the infected group compared to normal controls (n = 19) (Fig. 1d). Analysing the leading edge genes in the CHB 
(n = 30) and HCV (n = 23) cohorts identified 10 common genes, however, the majority of genes (57%) were 
unique to their respective cohorts.
We hypothesized that the hypoxic gene signature in CHB was mediated via inflammatory pathways. To evalu-
ate this assumption we studied enriched pathways in the CHB liver using the hallmark gene sets from MSigDB. 
This analysis identified genes associated with allograft rejection as the most significantly upregulated gene set in 
CHB. Interestingly HIF-1α was one of the leading-edge genes in this subset; contributing significantly to the core 
enrichment score. We noted increased HIF-1α mRNA levels in the CHB patients compared to control subjects 
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Figure 1.  Increased hypoxia gene expression in CHB. Hypoxia upregulated gene signatures from Molecular 
Signatures Database were assessed in the CHB cohort, 19 significantly upregulated gene signatures identified 
(FDR < 0.05) and ranked by Normalized Enrichment Score (NES) (a). GSEA shows a significant enrichment 
of HepG2 defined hypoxic genes in CHB cohort (FDR = 0.077). The gene set was based on Fold Change > 2, 
and FDR < 0.05; 80 genes satisfied these criteria and are listed in Supplementary Table 2 (b). CHB cohort 
was grouped by peripheral ALT activity, with subjects > 40 IU/L (n = 57) or < 40 IU/L (n = 25). GSEA shows a 
significant enrichment of HepG2 defined hypoxic genes in patients with elevated ALT (FDR = 0.110) (c). HepG2 
hypoxic gene set was enriched (FDR = 0.006) in HCV infected patients with cirrhosis (n = 41) compared to 
normal liver controls (n = 19) (d). MSigDB hallmark gene sets identified the most upregulated pathways in the 
CHB cohort: 28 gene sets were significantly enriched (FDR < 0.05) and are ranked by NES (e). All GSEA was 
performed using GSEA_4.0.371.
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(Log2 FC = 2.648, p = 0.005). Moreover, we observed a significant increase in inflammatory signaling pathways 
in CHB liver: TNF-α signaling via NF-κB’, ‘Inflammatory Response’ and ‘Interferon Gamma Response’ (Fig. 1e). 
In summary these data support the conclusion that the hypoxic phenotype in the diseased liver is likely driven 
by local inflammation, rather than a direct result of viral infection.
Limited evidence for HBx to stabilise HIF‑1α or HIF‑2α expression or associated transcriptional 
activity in vitro. As HBx is the major viral encoded transcriptional activator, previously reported to stabi-
lize  HIFs32–40, we used the bipotent HepaRG cell line expressing HBx (HepaRG-HBxWT) under a tetracycline 
(Tet) inducible  promoter50,51 to study HBx-HIF interplay. HBx promotes viral transcription by degrading the 
host structural maintenance of chromosomes (Smc) complex Smc5/652 and we confirmed that Tet induced HBx 
expression, loss of Smc6 expression (Fig. 2a) and restored replication of a defective HBV mutant lacking HBx 
Figure 2.  Effect of HBx on HIF expression and transcriptional activity in HepaRG cells. HepaRG cells encoding 
HBx were incubated with Tet (50 µM) for 24 h and HBx protein and Smc6 expression detected by western blot, 
uncropped blots are available in Supplementary Fig. 2 (a). Differentiated HepaRG cells encoding WT or mutated 
HBx (STOP) were treated or not with tetracycline (1 µM) and infected with  HBVWT or  HBVX- and 13 days later 
infection assessed by measuring total viral RNAs. The data is normalised for each cell line relative to  HBVWT 
infection without Tet and represent the mean of 3 independent experiments; 2-way-ANOVA with Bonferroni 
correction was applied with p < 0.05 deemed as significant (b). HepaRG cells encoding WT or mutated HBx 
(STOP) were incubated with or without Tet (50 μM, 24 h) and cultured under 20% or 1% oxygen conditions 
for 24 h. Cells were lysed and expression of HIF-1α, HIF-2α, Carbonic anhydrase IX (CAIX) and housekeeping 
gene B-actin assessed by western blotting, uncropped blots are available in Supplementary Figs. 3 and 4 (c) and 
mRNA levels of HIF-1α, HIF-2α and several HIF target genes (CAIX, BNIP3, VEGFA and GLUT1) quantified 
by qPCR (d). HepaRG cells encoding wild type HBx were incubated with Tet (50 µM, 24 h) and cultured at 20% 
or 1% oxygen for 24 h. The hypoxic cultures were returned to 20% oxygen. After 10 or 20 min, cells were lysed 
and screened for HIF-1α or HIF-2α and housekeeping gene β-actin expression by western blot, uncropped blots 
are available in Supplementary Fig. 5 (e). The data is shown from a single experiment and is representative of 
three independent experiments and represents mean ± standard deviation. Normality distribution was assessed 
by D’Agostino-Pearson test; 2-way-ANOVA with Bonferroni correction was applied with p < 0.05 deemed as 
significant.
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in differentiated HepaRG-HBxWT cells (Fig. 2b). Thus we confirm that HBx in this model system is functionally 
active. As a control for these experiments we generated HepaRG cells encoding HBx with three nonsense muta-
tions (HepaRG-HBxSTOP). To assess whether HBx can promote or stabilize HIF expression we treated HepaRG-
HBxWT or HepaRG-HBxSTOP cells with Tet and cultured at 1% oxygen, a typical oxygen concentration used to 
model hypoxia ex vivo, or standard ‘normoxic’ laboratory conditions of 20% oxygen for 24 h. HBx had minimal 
impact on HIF-1α or HIF-2α protein (Fig. 2c) or mRNA levels (Fig. 2d) in HepaRG cells cultured at 20% oxygen. 
Culturing HepaRG-HBxWT or HepaRG-HBxSTOP cells under 1% oxygen confirmed HIF-1α or HIF-2α expres-
sion and importantly showed a negligible effect of HBx on either HIF isoform (Fig. 2c). To assess whether HBx 
altered HIF transcriptional activity we quantified the mRNA levels of four HIF-regulated host genes (CAIX, 
BNIP3, VEGFA or GLUT1) (Fig. 2d) and CAIX protein expression (Fig. 2c) and observed no differences. Under 
normoxic conditions HIFs are hydroxylated by the oxygen-dependent PHDs and targeted for proteosomal deg-
radation. Oxygen reperfusion of hypoxic cells results in a time-dependent loss of HIFs and we assessed whether 
the presence of HBx could alter the kinetics of HIF expression. A comparable decrease in HIF-1α and HIF-2α 
proteins was seen after 10–20 min of oxygen reperfusion in both Tet treated and untreated cells (Fig. 2e), dem-
onstrating that HBx has a negligible effect on the kinetics of HIF degradation. In summary, we demonstrate that 
HepaRG cells are responsive to low oxygen and show a significant increase in hypoxia-associated gene transcrip-
tion, this effect was not impacted by the co-expression of HBx.
To further investigate a role for HBx to stabilize HIF-1α, we used an adenoviral vector engineered to express 
HBx (Ad-HBx) and showed HBx expression and Smc6 degradation. Transducing HepG2-NTCP cells with Ad-
HBx restored the replication of  HBVX- further demonstrating its functional activity (Fig. 3a). HepG2-NTCP cells 
transduced with Ad-HBx or Ad-OVA (adenoviral vector expressing ovalbumin) were cultured at 20% or 1% 
oxygen and cells harvested over a 48 h period. We confirmed HBx expression 24 h post-transduction (Fig. 3b) 
and observed expression of HIF-1α after 8 h at 1%  O2. Comparable expression levels of HIF-1α were noted in both 
Ad-HBx and Ad-OVA transduced cells, demonstrating a negligible effect of HBx on HIF-1α induction. These 
results further highlight a minimal role of HBx in regulating HIF-1α or HIF-2α mRNA or protein expression.
Figure 3.  Effect of HBx expression on HIF expression and transcriptional activity in HepG2 cells. HepG2-
NTCP cells were transduced with Ad-HBx and 24 h later the cells were probed for HBx and Smc6 expression by 
western blot, uncropped blots are available in Supplementary Fig. 6. In parallel experiments HepG2-NTCP cells 
were infected with HBV or a mutated virus lacking HBx  (HBVX-) (MOI of 200) in the presence or absence of 
Ad-HBx and the major viral transcript, pregenomic RNA measured at 6 days post-infection (a). HepG2-NTCP 
cells were transduced with Ad-HBx or Ad-OVA and HBx and HIF-1α expression assessed at selected times after 
culturing at either 20% or 1% oxygen, uncropped blots are available in Supplementary Figs. 7 and 8 (b). Data is 
shown from a single experiment and is representative of three independent experiments where the mean data is 
presented. Statistical analysis was performed with Kruskal–Wallis test, with multiple comparisons adjusted by 
Dunn’s correction.
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Studying HIF transcriptional activity in HBV transgenic mice. Since HBV can only infect humans 
and hominoid primates, no immune competent animal models are available that support natural HBV infec-
tion. One of the most-widely used murine models for studying CHB are transgenic mice expressing HBV from a 
single integrated genome (HBVtg). HBVtg mice have been reported to develop HCC that show similar chromo-
somal aberrations and gene expression patterns to human HBV-associated  HCC53. To study the effect of HBV on 
HIF transcriptional activity in this model system, HBVtg mice were treated with lipid nanoparticle complexed, 
liver-targeted siRNAs designed to silence all HBV transcripts (siHBV)54 or with an unspecific control siRNA 
(siCtrl). The HBV-specific siRNA led to effective HBV silencing with greater than 95% reduction in HBeAg in 
the serum (Fig. 4a) and viral transcripts in the liver (Fig. 4b). However, silencing HBV mRNAs and antigens had 
no impact on HIF regulated gene transcripts (CAIX, VEGFA, GLUT1 and PHD2) (Fig. 4b). These studies suggest 
a minimal role of HBV encoded proteins or RNAs in promoting HIF transcriptional activity.
Studying HIF transcriptional activity in HBV infected hepatocytes and human liver chimeric 
mice. To complement the HBx studies described above we investigated the effect of HBV infection on HIF 
oxygen sensing pathways in current state-of-the-art in  vitro and in  vivo models. HepG2-NTCP cells were 
infected with HBV and cultured under normoxic conditions and sampled after 3 and 9 days to assess HIF-1α or 
HIF-2α expression. HBV gene expression was confirmed by measuring HBeAg (53.96 ± 2.7 IU/mL) and HBsAg 
(12.63 ± 4.4 IU/mL), however, we failed to detect either HIF or CAIX expression in the infected or non-infected 
cells (Fig. 5a). As a control we treated HepG2-NTCP cells with a HIF PHD inhibitor (FG4592 at 30 µM) and 
demonstrated HIF protein expression (Fig. 5a). Analyzing published RNA-seq data from HBV infected primary 
human  hepatocytes55 showed no evidence of hypoxic gene upregulation (Fig. 5b). To further validate our conclu-
sions we used the chimeric human liver FNRG mouse  model56 to assess whether HBV infection would induce 
HIF signaling in this model. Female FNRG  mice56 between 8–12 weeks of age were transplanted with 0.5 × 106 
cryopreserved adult human hepatocytes by intrasplenic injection and monitored for engraftment by measuring 
human albumin levels in the serum (at least 0.1 mg human albumin per mL in peripheral blood). Engrafted 
animals were infected with 0.5 million genome equivalent (GE) copies of HBV per mouse and were monitored 
for HBV replication. Once stable viremia was established (minimum 5 × 107 GE  mL−1 of serum) the mice were 
sacrificed and livers harvested from HBV infected (n = 4) and uninfected (n = 3) animals for RNA isolation and 
RNA-seq. Analyzing these RNA-seq data sets showed minimal evidence for an increase in hypoxic transcrip-
tional activity in the HBV infected livers (Fig. 5b). For comparative purposes, we show that hypoxic genes were 
Figure 4.  Effect of silencing viral transcription in HBV transgenic mice on hypoxia target gene transcripts. 
HBV transgenic mice (n = 6 per group) were treated with liver directed siRNAs targeting the HBx region 
(siHBV) which is commonly shared by all viral RNAs or with a control siRNA (siCtrl). Seven days later we 
assessed the efficacy of siHBV silencing by quantifying: serum HBeAg levels (a), HBV RNAs in the liver and 
hypoxia target gene (CAIX, VEGFA, GLUT1 and PHD2) RNAs (b). Hypoxia target genes values are expressed 
as ΔCt values by subtracting the Ct value of the housekeeping gene β-actin from Ct value of the gene of interest. 
Mann Whitney (a) or 2-way-ANOVA with Bonferroni correction (b) analyses were applied with p < 0.05 
deemed as significant.
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upregulated in the CHB  cohort41 (Fig. 5b), demonstrating the influence of inflammation on gene regulation and 
highlighting the limitations of current HBV replication models to model CHB.
Discussion
In this study we identified increased hypoxia gene signatures in a CHB cohort in the absence of cirrhosis or HCC. 
We confirmed hypoxic gene expression using MSigDB derived gene sets and recently reported signatures from 
 HepG244 and PHH data  sets45. We noted an increase in HIF-1α mRNA levels, consistent with their transcriptional 
regulation by inflammatory mediators such as TNFα. Given previous reports that HBx can stabilize  HIFs32–40,57, 
we investigated whether functionally active HBx could regulate endogenous HIF-1α and HIF-2α mRNA, protein 
and transcriptional activity in vitro. We found minimal evidence for HBx regulation of HIFs in three independ-
ent model systems: an inducible HepaRG-HBx cell line; an Ad-HBx transduced cell, and in de novo infection 
of HepG2-NTCP or PHHs. Our study is distinct from earlier reports on at least three counts. Firstly, due to the 
technical difficulties in visualizing HBx by western blotting or immunofluorescent imaging, many of the earlier 
studies did not confirm HBx expression. Secondly, the majority of studies did not validate the functional activ-
ity of the expressed HBx protein. Finally, several studies assessed HBx stabilization of HIF-1α using transient 
plasmid transfection systems with hypoxia reporter constructs, rather than directly measuring HIF expression 
and HIF target gene modulation. Given our current knowledge that HBx degrades Smc6 that silences episomal 
DNA transcription, the interpretation of these earlier plasmid based  systems58 is now uncertain. Since we have 
directly confirmed expression and function of HBx in our in vitro models and quantified endogenous HIF tran-
scriptional activity under normoxic or hypoxic conditions we are confident that HBx does not modulate HIF 
expression or transcriptional activity in the model systems used.
Guerrieri et al. identified and validated a role for HBx in regulating genes involved in endocytosis, predomi-
nantly members of the Ras-related in brain (Rab)  family9. Anti-HBx chromatin immunoprecipitation studies 
Figure 5.  Comparing hypoxia gene signatures in HBV infected hepatocytes and humanized liver chimeric 
mice. Mock or HBV-infected HepG2-NTCP cells (MOI 200) were harvested after 3 or 9 days, lysed and assessed 
for HIF-1α, HIF-2α or CAIX expression and the housekeeping gene B-actin by western blotting. As a positive 
control HepG2-NTCP cells were treated with the HIF PHD inhibitor FG4592 (FG, 30 μM) for 24 h and protein 
lysates analysed by western blotting, uncropped blots are available in Supplementary Fig. 9 (a). Induction of 
hypoxic genes (Supplementary Table 2) in transcriptomic data of HBV infected primary human  hepatocytes55, 
HBV infected human liver chimeric mice and a CHB cohort (b). Fold change was calculated for each of the 
80 genes in HBV infection against the healthy controls, where the dotted line represents a twofold change. For 
the CHB cohort, fold change was calculated from the raw Affymetrix, differential expression was tested using 
multiple t-tests and significance determined by (adjusted p value < 0.05).
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identified HBx binding sites that included RAB1A, RAB2B and RAB5B promoters and none of the validated 
Rab genes were listed in our hypoxic gene set (Supplementary Table 2). Furthermore, GSEA of the CHB cohort 
or screening reactome gene sets showed only a modest enrichment in the ’Transferrin Endocytosis’ pathway 
(Fig. 1e), suggesting a minimal overlap between HBx and HIF regulated genes.
Our results support a model where HBV infection associated inflammatory responses promote HIF expression 
and these complex virus-cell interactions are not recapitulated by simple in vitro culture systems, HBV trans-
genic mice or immunodeficient SCID human liver chimeric mouse models. This conclusion is supported by our 
observation of increased hypoxic gene expression in a cohort of HCV infected patients with cirrhosis (Fig. 1d). 
Analyzing the leading edge genes from the HBV (n = 30) and HCV (n = 23) cohorts identified 10 common 
genes, suggesting some gene specific differences between these chronic infections. Our bio-informatic analysis 
identified 25 hypoxia upregulated genes in chronic HBV infected patients, including LOXL2, SMIM3, TNS1, and 
IGFBP1. Notably, LOXL2 overexpression in HCC was previously associated with high tumour grade, metasta-
sis, and poor patient overall and disease-free  survival59. LOXL2 was shown to mediate its pathogenic effects in 
HCC angiogenesis via vasculogenic mimicry signalling, cytoskeleton reorganization, and bone-marrow derived 
cell  recruitment59,60. In fact, hypoxia and HIF-1α signalling have been identified as key regulators of LOXL2 
and driver of its pathogenesis, consistent with our  observations60,61. Another significantly upregulated gene in 
chronic HBV patients, IGFBP1, was recently reported to be a HIF-2α regulated gene in vitro and in vivo model 
 systems62. Furthermore, IGFBP1 is a known NF-κB target gene and is induced by HBV  infection63. These data 
suggest co-regulation of IGFBP1 by inflammatory pathways including NF-κB and oxygen sensing mechanisms 
such as HIF signalling, which is consistent with our observation of inflammatory gene enrichment associating 
with hypoxia gene signature in CHB.
Our observation of increased hypoxic gene signature expression in CHB patients offers an important insight 
into HBV disease stage stratification and suggest areas for bio-marker discovery for early HCC detection. This 
is in agreement with previous studies that have associated higher HIFα mRNA and protein expression in HCC 
with worse prognostic outcomes for HCC  patients18–20. Moreover, as the liver is a naturally physiologically low 
oxygen environment, future investigations exploring how oxygen sensing pathways regulate HBV replication 
and pathogenesis may identify novel therapeutic targets.
Materials and methods
Cell lines and reagents. HepaRG cells expressing HBx under the control of a Tetracycline inducible pro-
moter were cultured in Williams E medium supplemented with 10% FBS, 50 IU penicillin/streptomycin  mL−1, 
5  μg human insulin  mL−1 and 5 × 10−7  M hydrocortisone hemisuccinate (Sigma). As a control we generated 
HepaRG cells expressing an inactive HBx null mutant (HepaRG-HBxSTOP) where three point nonsense muta-
tions (relative to EcoRI site: C to A, 1393nt; C to A, 1396nt and C to T, 1397nt) were introduced to generate 
three stop codons (respectively, TGA, 1393nt; TGA, 1396nt; TAA, 1397nt) in HBV genotype D. HepG2-NTCP 
 cells64 were maintained in Dulbecco’s Modified Eagles Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), 2 mM l-glutamine, 1 mM Sodium Pyruvate, 50 IU penicillin/streptomycin  mL-1 and non-essential 
amino acids (Life Technologies, UK). HIF PHD inhibitor FG4592 was purchased from Cambridge Biosciences, 
UK. Cells were incubated under hypoxia in an atmosphere-regulated chamber with 1%  O2: 5%  CO2: balance  N2 
(Invivo 400, Baker-Ruskinn Technologies). The Ad-HBx and Ad-Ova express the HBV genotype D HBx gene 
and chicken ovalbumin gene under control of the Transthyretin (TTR) promoter. Promoter and insert were 
inserted into the E1 region of adenovirus (Ad5ΔE1/E3) backbone plasmid pAd/PL-DEST through Gateway 
recombination following the manufacturer’s instructions (Gateway System; Invitrogen, Karlsruhe, Germany). 
Adeno virus stocks were titrated using the cytopathic effect in HepG2 cells as previously  described65.
HBV genesis and infection. HBV was purified from a HepAD38 producer line as previously  reported64. 
Briefly, virus was purified using centrifugal filter devices (Centricon Plus-70 and Biomax 100.000, Millipore 
Corp., Bedford, MA) and stocks with a titre between 3 × 109 and 3 × 1010 viral genome equivalents (vge) per mL 
stored at − 80 °C. HBV-X- virus was purified from a HepG2 based cell line containing a HBV 1.3 × overlength 
integrated viral genome where both 5′ and 3′ HBx genes were knocked out by a point mutation that changes the 
eight amino acid to a stop codon (CAA-to-TAA) as previously  described51. HepG2-NTCP cells were treated with 
2.5% dimethyl sulphoxide (DMSO) for 3 days and inoculated with HBV at an MOI of 200 in the presence of 4% 
polyethylene glycol 8,000. After 18-20 h the inoculum was removed by washing with PBS and the cells cultured 
in the presence of 2.5% DMSO. Secreted HBe and HBs antigen were quantified by ELISA (Autobio, China).
SDS‑PAGE and Western blotting. Samples were harvested using RIPA lysis buffer (20 mM Tris, pH 7.5, 
2 mM EDTA, 150 mM NaCl, 1% NP40, 1% sodium deoxycholate, and Roche protease inhibitor cocktail tablets). 
Lysed samples were mixed with 4 × reducing buffer, and incubated at 95 °C for 5 min. A 10% polyacrylamide 
gel was used for protein separation and transferred to PVDF membranes (Amersham). Membranes were cut at 
the 70 kDa molecular weight mark, blocked in PBST, 5% skimmed milk (Sigma), and incubated overnight with 
respective primary antibodies, as listed below. Blots were incubated in a 1:3,000 dilution of poly-clonal goat anti-
mouse immunoglobulins/HRP (Dako (P0447) secondary antibody, before developing with Pierce SuperSignal 
West Pico chemiluminescent substrate kit. Images were captured with a ChemiDoc XRS + imaging system (Bio-
Rad). Where blots were sequentially probed for proteins of similar molecular weights, membranes were stripped 
in 0.5 M NaOH for 5 min, before thorough washing with PBST, and blocking for 1 h in PBST 5% skimmed milk 
before re-probing. The following primary antibodies were used at the listed dilutions in this study: HIF-1α, 
1:1,000 (BD Biosciences: 610,959); anti-HIF-2α, 1:1,000 (Novus: NB100-132); anti-β-actin, 1:5,000 (Sigma: 
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A5441); anti-SMC6, 1:1,000 (Abgent: AT3956a); anti-HBx, 1:500 (Abcam: AB39716); and anti-CAIX, 1:1,000 
(Adrian Harris laboratory: University of Oxford).
PCR quantification of HBV RNA and HIF gene transcripts. Total cellular RNA was extracted using 
an RNeasy mini kit (Qiagen) following the manufacturer’s instructions and samples treated with RNase-Free 
DNaseI (14 Kunitz units/rxn, Qiagen) for 30 min at room temperature. RNA concentration was measured by 
NanoDrop 1,000 spectrophotometer (Thermo Scientific) and cDNA synthesized with 0.25-1 µg of RNA in a 
20 µL total reaction volume using a random hexamer/oligo dT strand synthesis kit in accordance with the manu-
facturer’s instructions (10 min at 25 °C; 15 min at 42 °C; 15 min at 48 °C; SensiFast, Bioline). PCR amplification 
of HBV RNAs were performed using primers as previously  described50 using a SYBR green real-time PCR proto-
col (qPCRBIO SyGreen, PCR Biosystems) in a Lightcycler 96™ instrument (Roche). The amplification conditions 
were: 95 °C for 2 min (enzyme activation), followed by 45 cycles of amplification (95 °C for 5 s; 60 °C for 30 s). 
HIF target genes were amplified using TaqMan® Gene Expression assays (CAIX [Hs00154208_m1]; VEGFA 
[Hs00900055_m1]; BNIP3 [Hs00969291_m1] and GLUT1 [Hs00892681_m1]) (Thermo Fisher) and amplified 
using a Taqman real-time PCR protocol (qPCRBIO probe, PCR Biosystems) using the same conditions as listed 
above.
HBV transgenic mice and siRNA delivery. Animal experiments were conducted in accordance with 
the German regulations of the Society for Laboratory Animal Science (GV-SOLAS) and the European Health 
Law of the Federation of Laboratory Animal Science Associations (FELASA). Experiments were approved by 
the local Animal Care and Use Committee of Upper Bavaria and followed the 3R rules. Mice were kept in a 
specific-pathogen-free facility under appropriate biosafety level following institutional guidelines. HBVtg mice 
(strain HBV1.3.32)66,67 carrying a 1.3-fold overlength HBV genome (genotype D) on a C57BL/6J background 
and both male and female mice between 12–15 weeks were used. The HBV specific siRNA (siHBV) was designed 
to silence all HBV transcripts by targeting the 3´region of the HBV genome and the control siRNA (siCtrl) does 
not target any viral or known host transcripts. siRNAs were complexed with Invivofectamine 3.0 reagent (Ther-
moFisher Scientific) before injecting 1 µg/g body weight into the tail vain. HBeAg was quantified from mouse 
sera after dilution with the Architect HBsAg Manual Diluent using the quantitative HBeAg Reagent Kit (Ref: 
6C32-27) with HBeAg Quantitative Calibrators (Ref.: 7P24-01) on an Architect TM platform (Abbott Laborato-
ries, Wiesbaden, Germany). Immediately after sacrificing the mice and preparation of the liver, an approximately 
0.4 mm thick and 1–1.5 cm long peace of liver was placed in 500µL RNAlater. After storage for 24 h at 4 °C (to 
allow RNA later to penetrate tissue) the tissue was transferred to − 20 °C and stored until RNA preparation. RNA 
was prepared using the RNeasy Mini kit (Qiagen), where an approximate 20 mg piece of frozen liver was placed 
in a 2 mL micro-centrifuge tube pre-cooled on dry ice. After adding 600µL of Buffer RLT, tissue was homog-
enized using the TissueLyser LT (Qiagen) for 5 min at 50 Hz. Total RNA was extracted following the protocol 
of the RNeasy mini kit.
HBV infected human chimeric mice and RNA‑sequencing. Mock and HBV infected mice were sac-
rificed and livers harvested for RNA isolation and RNA-sequencing at the Beijing Genomics Institute (BGI, 
Hong Kong). RNA purity was assessed with a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific) 
and integrity determined using a 2100 Bioanalyzer Instrument (Agilent Technologies). Sequencing was per-
formed on a BGISEQ-500 (Beijing Genomics Institute, Hong Kong) employing the PE100 mode to produce raw 
paired‐end reads of 100 bp and SOAPnuke (v1.5.2) software to filter out non-human sequencing reads, as previ-
ously  reported57,68,69. Clean reads (FASTQ files) were uploaded to Partek Flow (version 8.0, build 8.0.19.1125; 
Partek Inc., St. Louis, MO, USA), quality-controlled, and aligned to the human genome (hg38) with STAR-2.6.1d 
aligner software. Genes were quantified using the transcript model Ensembl Transcripts release 91 and dif-
ferential expression determined with DESeq2 (3.5). Microarray analysis was performed with Partek Genomics 
Suite (v6.6) as previously  described70. Scatter dot plots of fold change values were plotted with Graphpad Prism 
version 8. RNA-seq data are deposited in the GEO archive at NCBI, with the accession number GSE145835 and 
entitled: Transcriptional profiling of hepatocytes isolated from chronically HBV-infected human liver chimeric 
mice.
Gene set enrichment analysis. GSEA was performed with GSEA_4.0.371 using publicly available Affym-
etrix microarray  datasets41,49 from Gene Expression Omnibus (GEO) (accessions: GSE83148, GSE14323). Gene 
sets were derived from HepG2 RNA-seq  data44 downloaded from GEO (GSE120886) or PHH RNA-Seq accessed 
from the published Supplementary  Material45. To determine whether HBV infection induces hypoxia-respon-
sive genes, we interrogated the mRNA expression patterns of the liver chimeric mice RNA-Seq dataset for the top 
80 hypoxia-induced genes as identified in HepG2 hepatic  cells44. In-house datasets were compared with RNA-
seq55 from HBV-infected primary human hepatocytes. Data were retrieved from GEO (accessions: GSE120886, 
GSE93153, GSE118295). For consistency, all datasets were re-analysed with the same Partek Flow bioinformatic 
pipeline. Microarray analysis was performed with Partek Genomics Suite (v6.6) as previously  described70 and 
data presented using Graphpad Prism 8.
Statistical analyses. All analyses were performed using Prism 8 (GraphPad, La Jolla, CA). Data are shown 
as means ± SD, probabilities are indicated by *p < 0.05, **p < 0.01, ***p < 0.001 or ****p < 0.0001, with Bonferroni 
corrections for multiple testing when appropriate.
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Data availability
RNA-seq data from HBV infected mice are deposited in the GEO archive at NCBI, with the accession number 
GSE145835 and entitled: Transcriptional profiling of hepatocytes isolated from chronically HBV-infected human 
liver chimeric mice. Our in-house data was compared with RNA-seq55 from HBV-infected primary human 
hepatocytes and data retrieved from GEO (accessions: GSE120886, GSE93153, GSE118295).
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